Literature DB >> 19254720

Development of forward genetics in Toxoplasma gondii.

L David Sibley1.   

Abstract

The development of forward genetics as a functional system in Toxoplasma gondii spanned more than three decades from the mid-1970s until now. The initial demonstration of experimental genetics relied on chemically induced drug-resistant mutants that were crossed by co-infecting cats, collecting oocysts, sporulating and hatching progeny in vitro. To capitalise on this, genetic markers were employed to develop linkage maps by tracking inheritance through experimental crosses. In all, three generations of genetic maps were developed to define the chromosomes, estimate recombination rates and provide a system for linkage analysis. Ultimately this genetic map would become the foundation for the assembly of the T. gondii genome, which was derived from whole genome shotgun sequencing, into a chromosome-centric view. Finally, application of forward genetics to multigenic biological traits showed the potential to map and identify specific genes that control complex phenotypes including virulence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19254720      PMCID: PMC2705751          DOI: 10.1016/j.ijpara.2009.02.011

Source DB:  PubMed          Journal:  Int J Parasitol        ISSN: 0020-7519            Impact factor:   3.981


  71 in total

1.  Construction of a molecular karyotype for Toxoplasma gondii.

Authors:  L D Sibley; J C Boothroyd
Journal:  Mol Biochem Parasitol       Date:  1992-04       Impact factor: 1.759

2.  Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group.

Authors:  B Dannemann; J A McCutchan; D Israelski; D Antoniskis; C Leport; B Luft; J Nussbaum; N Clumeck; P Morlat; J Chiu
Journal:  Ann Intern Med       Date:  1992-01-01       Impact factor: 25.391

3.  Mapping mendelian factors underlying quantitative traits using RFLP linkage maps.

Authors:  E S Lander; D Botstein
Journal:  Genetics       Date:  1989-01       Impact factor: 4.562

4.  Toxoplasma gondii: characterization of a mutant resistant to sulfonamides.

Authors:  E R Pfefferkorn; S E Borotz; R F Nothnagel
Journal:  Exp Parasitol       Date:  1992-05       Impact factor: 2.011

5.  Toxoplasma gondii: purine synthesis and salvage in mutant host cells and parasites.

Authors:  J D Schwartzman; E R Pfefferkorn
Journal:  Exp Parasitol       Date:  1982-02       Impact factor: 2.011

6.  Toxoplasma gondii: in vivo and in vitro studies of a mutant resistant to arprinocid-N-oxide.

Authors:  E R Pfefferkorn; M E Eckel; E McAdams
Journal:  Exp Parasitol       Date:  1988-04       Impact factor: 2.011

7.  Parasiticidal effect of clindamycin on Toxoplasma gondii grown in cultured cells and selection of a drug-resistant mutant.

Authors:  E R Pfefferkorn; R F Nothnagel; S E Borotz
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

8.  MAPMAKER: an interactive computer package for constructing primary genetic linkage maps of experimental and natural populations.

Authors:  E S Lander; P Green; J Abrahamson; A Barlow; M J Daly; S E Lincoln; L A Newberg; L Newburg
Journal:  Genomics       Date:  1987-10       Impact factor: 5.736

9.  Toxoplasma gondii: genetic crosses reveal phenotypic suppression of hydroxyurea resistance by fluorodeoxyuridine resistance.

Authors:  E R Pfefferkorn; L H Kasper
Journal:  Exp Parasitol       Date:  1983-04       Impact factor: 2.011

10.  Determination of nuclear DNA of five eucoccidian parasites, Isospora (Toxoplasma) gondii, Sarcocystis cruzi, Eimeria tenella, E. acervulina and Plasmodium berghei, with special reference to gamontogenesis and meiosis in I. (T.) gondii.

Authors:  A W Cornelissen; J P Overdulve; M van der Ploeg
Journal:  Parasitology       Date:  1984-06       Impact factor: 3.234

View more
  9 in total

1.  Genetic mapping reveals that sinefungin resistance in Toxoplasma gondii is controlled by a putative amino acid transporter locus that can be used as a negative selectable marker.

Authors:  Michael S Behnke; Asis Khan; L David Sibley
Journal:  Eukaryot Cell       Date:  2014-12-05

Review 2.  Molecular parasitology in the 21st century.

Authors:  Roberto Docampo
Journal:  Essays Biochem       Date:  2011       Impact factor: 8.000

Review 3.  Strategies to discover the structural components of cyst and oocyst walls.

Authors:  John Samuelson; G Guy Bushkin; Aparajita Chatterjee; Phillips W Robbins
Journal:  Eukaryot Cell       Date:  2013-10-04

Review 4.  Modulation of innate immunity by Toxoplasma gondii virulence effectors.

Authors:  Christopher A Hunter; L David Sibley
Journal:  Nat Rev Microbiol       Date:  2012-11       Impact factor: 60.633

5.  Genetic and molecular basis of drug resistance and species-specific drug action in schistosome parasites.

Authors:  Claudia L L Valentim; Donato Cioli; Frédéric D Chevalier; Xiaohang Cao; Alexander B Taylor; Stephen P Holloway; Livia Pica-Mattoccia; Alessandra Guidi; Annalisa Basso; Isheng J Tsai; Matthew Berriman; Claudia Carvalho-Queiroz; Marcio Almeida; Hector Aguilar; Doug E Frantz; P John Hart; Philip T LoVerde; Timothy J C Anderson
Journal:  Science       Date:  2013-11-21       Impact factor: 47.728

6.  A century of Toxoplasma research.

Authors:  James W Ajioka; Naomi S Morrissette
Journal:  Int J Parasitol       Date:  2009-02-25       Impact factor: 3.981

7.  The early years of Toxoplasma research: What's past is prologue.

Authors:  Naomi S Morrissette; James W Ajioka
Journal:  Int J Parasitol       Date:  2009-02-27       Impact factor: 3.981

8.  Congenital toxoplasmosis: an in-depth density-equalizing mapping analysis to explore its global research architecture.

Authors:  Dörthe Brüggmann; Vanessa Handl; Doris Klingelhöfer; Jenny Jaque; David A Groneberg
Journal:  Parasit Vectors       Date:  2015-12-21       Impact factor: 3.876

9.  A major genetic locus in Trypanosoma brucei is a determinant of host pathology.

Authors:  Liam J Morrison; Andy Tait; Sarah McLellan; Lindsay Sweeney; C Michael R Turner; Annette MacLeod
Journal:  PLoS Negl Trop Dis       Date:  2009-12-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.